Found 38 matching trials
A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) PHASE2 A total of 516 healthy subjects aged 18 years and above who have been vacci...
Show More Location
Sheikh Khalifa Medical City
Learn More & Join Trial
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years EARLY_PHASE1 Increased immune escape of emerging SARS-CoV-2 variants and waning neutrali...
Show More Location
The Fifth Affiliated Hospital of Guangzhou Medical University
Learn More & Join Trial
Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell) PHASE1 This is a phase I, randomized, placebo-controlled, double-blind study, to e...
Show More Location
Jiangsu Provincial Center for Diseases Control and Prevention
Treatments Being Tested
Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 Two doses of placebo at the schedule of day 0, 14 #middle-dose group# Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group# Two doses of placebo at the schedule of day 0, 14 #High-dose group# Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group# Learn More & Join Trial
Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 PHASE1 The purpose of this double-blind, randomized, controlled study is to assess...
Show More Location
Xiangcheng Center for Disease Control and Prevention
Learn More & Join Trial
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial PHASE3 This clinical trial adopts a randomized, double-blind and placebo-controlle...
Show More Location
Sheikh Khalifa Medical City
Learn More & Join Trial
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001 EARLY_PHASE1 The goal of this clinical trial is to assess the immunogenicity and safety ...
Show More Location
Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College
Learn More & Join Trial
Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells) PHASE2 This is a phase Ⅱ, randomized, placebo-controlled, double-blind study, to e...
Show More Location
Jiangsu Provincial Center for Diseases Control and Prevention
Treatments Being Tested
a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56 a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56 a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56 a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56 a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56 a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56 a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56 a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56 Learn More & Join Trial
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2 NA An open experimental design was used in this study, and 240 subjects were p...
Show More Location
Hunan Provincial Center for Disease Control and Prevention
Learn More & Join Trial
Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 PHASE2 The purpose of this double-blind, randomized, controlled study is to assess...
Show More Location
Xiangcheng Center for Disease Control and Prevention
Learn More & Join Trial
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above PHASE2 This is randomized, blinded and controlled design. Among the randomly selec...
Show More Location
Sheikh Khalifa Medical City
Learn More & Join Trial